Sense Diagnostics

Low power “radar for brain” detects active bleeding/blood flow...


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

Serious Problem

Strokes and traumatic brain injuries (TBI) are a far more serious problem than many realize. Many patients die or are left severely disabled.

It is especially problematic in that preventable delays occur in detecting severe strokes and brain trauma in patients.

Medical professionals need to be able to catch worsening brain conditions sooner between CT scans, before additional brain damage occurs.


I N D U S T R Y
Medical devices/diagnostics


M A R K ET  S I Z E
$3 Billion+


T A R G E T  C U S T O M E R
Hospital emergency rooms + neurology departments, as well as emergency medical services providers (for use in their ambulances)

3 Million Americans

Delays occur:

Innovative Solution

Sense Diagnostics is solving this problem by developing a scanner that:

Once in the hospital, our scanner is able to:

How It Works

Our Sense Brain Injury Scanner is unique in that it passes low-power radio waves through the patient's head.

The signals are scattered and absorbed differently by each type of the brain's tissue.

Blood, grey/white matter and cerebral spinal fluid all affect the waves differently, which allows us to identify areas of:

Bleeding
Swelling
Blocked blood vessels

Extensive Research

During the course of development, along with securing FDA approval, we have conducted extensive market research with:

Meet The Team

Daniel Kincaid, JD | CEO

  • Successful health care executive, entrepreneur (having taken a health IT company from founding to exit) and seed stage investor
  • Mr. Kincaid has been critical to ensuring that Sense Diagnostics pursues and protects business aspects of device development
  • This includes:
    • Determining a regulatory pathway
    • Intellectual property protection
    • Development of a viable business plan

Joseph Korfhagen, PhD | Director, Research and Development

  • Dr. Korfhagen has spent the last eight years developing the Sense device from an idea to a working prototype
  • He successfully defended his dissertation in 2014 on this project and obtained a Ph.D. in Neuroscience
  • His research and professional experience related to this device include neuroanatomy, electromagnetics, software development, and medical device design

George J. Shaw, MD, PhD | Co-Founder and Chief Technology Officer

  • Dr. Shaw is a PhD physicist and physician who will have both a clinical and technical role in developing our technology
  • His lab at the University of Cincinnati obtained the pilot data for the Sense device
  • In addition, he is a practicing Emergency Medicine physician and has conducted NIH-funded clinical trials in the area of traumatic brain injury
  • He serves as the ‘technical lead’ for current and
  • future development of the Sense device
  • He is also an Associate Professor of Emergency Medicine at the University of Cincinnati

Opeolu Adeoye, MD | Co-Founder and Chief Medical Officer

  • Adeoye is Co-Director of the UC Stroke Team
  • He is a certified neurocritical care physician who attends in the University of Cincinnati Medical Center’s neurocritical care unit
  • Serves as regional coordinator of the NIH Strokenet (one of 20 nationwide)
  • Awarded largest grant in NIH history for studying emergency medicine ($29mm for studying tPA combination therapy for stroke)
  • Dr. Adeoye is an experienced clinical trialist, having served as PI of multiple NIH-funded stroke and TBI-related clinical trials
  • He now serves on the American Stroke Association’s Scientific Oversight Committee
  • He previously served on the Neurocritical Care Society’s Annual Meeting Planning Committee and as a Liaison between the Neurocritical Care Society and the Society for Academic Emergency Medicine
  • Further, Adeoye is an Associate Professor of Emergency Medicine and Neurosurgery at the University of Cincinnati

Matthew Flaherty, MD | Co-Founder and Chief Clinical Officer

  • Neurologist at the UC Neuroscience Institute
  • A member of the highly-regarded UC Stroke Team
  • Professor of Neurology at the UC College of Medicine
  • Dr. Flaherty practices general neurology with an emphasis upon stroke care
  • He is a prolific author in the area of cerebrovascular disease, and was awarded the Michael S. Pessin Stroke Leadership Prize by the American Academy of Neurology in 2009
  • At UC, he has participated in numerous stroke-related clinical studies and research projects

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.co platform

Copyright © 2017 Startups.co. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.